Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

Abeona Therapeutics transitions to a commercial-stage company with ZEVASKYN's FDA approval, QTC activation, and a PRV sale boosting operations toward ...

The U.S. Food and Drug Administration (FDA) has approved prademagene zamikeracel (Zevaskyn) for the treatment of blistering ...

Abeona Therapeutics Inc. (Nasdaq: ABEO), a Cleveland-based biotech company, announced Monday, May 12, that it has entered an ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Q1 2025 Earnings Call Transcript May 16, 2025 Operator: Good day and welcome to the Abeona Therapeutics First Quarter 2025 ...

Lurie Children’s is set to begin evaluating patients for ZEVASKYN treatment in the third quarter of 2025, following its recent FDA approval. ZEVASKYN utilizes gene-corrected cellular sheets to ...

Abeona was awarded the PRV following the FDA approval of ZEVASKYN. “The proceeds from our PRV sale fully fund our operations for over two years, extending our runway through our projected ...

On April 29, 2025, Abeona announced approval from the U.S. Food and Drug Administration (FDA) for ZEVASKYN as the first and only autologous cell-based gene therapy for the treatment of wounds in ...

Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only ...

ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now ...

Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and ...